Copyright
©The Author(s) 2022.
World J Clin Cases. Oct 16, 2022; 10(29): 10451-10466
Published online Oct 16, 2022. doi: 10.12998/wjcc.v10.i29.10451
Published online Oct 16, 2022. doi: 10.12998/wjcc.v10.i29.10451
Table 1 General characteristics of Surveillance, Epidemiology and End Results and validation data sets
Variable | SEER data set (%), n = 5200 | Validation data set (%), n = 603 |
Age (yr) | ||
< 40 | 200 (3.85) | 41 (6.80) |
40-60 | 1389 (26.71) | 313 (51.91) |
60-80 | 2690 (51.73) | 236 (39.14) |
> 80 | 921 (17.71) | 13 (2.15) |
Sex | ||
Male | 2933 (56.40) | 423 (70.15) |
Female | 2267 (43.60) | 180 (29.85) |
Race | ||
White | 2947 (56.67) | |
Black | 830 (15.96) | |
Black-AI | 52 (1.00) | |
Black-API | 1371 (26.37) | |
T stage | ||
T1a | 597 (11.48) | 247 (40.96) |
T1b | 708 (13.62) | |
T2 | 693 (13.33) | 70 (11.61) |
T3 | 1697 (32.63) | 8 (1.33) |
T4a | 1155 (22.21) | 278 (46.10) |
T4b | 350 (6.73) | |
N stage | ||
N0 | 2233 (42.94) | 266 (44.11) |
N1 | 951 (18.29) | 184 (30.52) |
N2 | 855 (16.44) | 89 (14.76) |
N3 | 1161 (22.33) | 64 (10.61) |
AJCC stage | ||
I | 1580 (30.38) | 262 (43.45) |
II | 1449 (27.87) | 71 (11.77) |
III | 2171 (41.75) | 270 (44.78) |
Radiotherapy | ||
Yes | 1416 (27.23) | 16 (2.66) |
No | 3784 (72.77) | 587 (97.34) |
Chemotherapy | ||
Yes | 2599 (49.98) | 445 (73.80) |
No | 2601 (50.02) | 158 (26.20) |
Tumor size (cm) | ||
< 2 | 820 (15.77) | |
2-5 | 2198 (42.27) | 94 (15.59) |
> 5 | 1700 (32.69) | 393 (65.17) |
NA | 482 (9.27) | 116 (19.24) |
Histology | ||
SRC | 1326 (25.50) | 84 (13.93) |
Differentiated | 1550 (29.81) | 241 (39.97) |
Undifferentiated | 2324 (44.69) | 278 (46.10) |
Table 2 Comparison of general characteristics of patients with different differentiated types of gastric cancer
Variable | Differentiated (%), n = 1550 | P value | SRC (%), n = 1326 | P value | Undifferentiated (%), n = 2324 |
Age (yr) | |||||
< 40 | 13 (0.84) | < 0.001 | 110 (8.30) | < 0.001 | 77 (3.31) |
40-60 | 241 (15.55) | < 0.001 | 518 (39.06) | < 0.001 | 630 (27.11) |
60-80 | 920 (59.35) | < 0.001 | 583 (43.97) | < 0.001 | 1187 (51.08) |
> 80 | 376 (24.26) | < 0.001 | 115 (8.67) | < 0.001 | 430 (18.50) |
Sex | < 0.001 | < 0.001 | |||
Male | 959 (61.87) | 625 (47.13) | 1349 (58.05) | ||
Female | 591 (38.13) | 701 (52.87) | 975 (41.95) | ||
Race | |||||
White | 804 (51.87) | < 0.001 | 819 (61.74) | 0.005 | 1324 (56.97) |
Black | 295 (19.03) | 0.001 | 188 (14.19) | 0.536 | 347 (14.93) |
Black-AI | 16 (1.03) | 0.890 | 13 (0.98) | 0.978 | 23 (0.99) |
Black-API | 435 (28.07) | 0.002 | 306 (23.09) | 0.007 | 630 (27.11) |
T stage | |||||
T1a | 281 (18.13) | 0.004 | 187 (14.10) | < 0.001 | 129 (5.56) |
T1b | 325 (20.97) | < 0.001 | 126 (9.51) | 0.140 | 257 (11.06) |
T2 | 242 (15.61) | 0.002 | 155 (11.69) | 0.355 | 296 (12.74) |
T3 | 450 (29.03) | 0.930 | 383 (28.89) | < 0.001 | 864 (37.17) |
T4a | 171 (11.03) | < 0.001 | 385 (29.03) | 0.033 | 599 (25.77) |
T4b | 81 (5.23) | 0.078 | 90 (6.78) | 0.309 | 179 (7.70) |
N stage | |||||
N0 | 946 (61.03) | < 0.001 | 512 (38.61) | 0.001 | 775 (33.35) |
N1 | 278 (17.94) | 0.097 | 207 (15.61) | 0.001 | 466 (20.05) |
N2 | 181 (11.68) | 0.010 | 198 (14.93) | < 0.001 | 476 (20.48) |
N3 | 145 (9.35) | < 0.001 | 409 (30.85) | 0.002 | 607 (26.12) |
AJCC stage | |||||
I | 730 (47.10) | < 0.001 | 372 (28.05) | < 0.001 | 478 (20.57) |
II | 452 (29.16) | < 0.001 | 305 (23.00) | < 0.001 | 692 (29.78) |
III | 368 (23.74) | < 0.001 | 649 (48.95) | 0.679 | 1154 (49.65) |
Primary site | |||||
Fundus | 67 (4.32) | 0.084 | 41 (3.09) | 0.665 | 78 (3.36) |
Body | 198 (12.77) | 0.527 | 180 (13.58) | 0.898 | 319 (13.73) |
Antrum | 640 (41.29) | < 0.001 | 434 (32.73) | 0.061 | 832 (35.80) |
Pylorus | 85 (5.48) | 0.879 | 71 (5.36) | 0.687 | 132 (5.68) |
Lesser curve | 228 (14.71) | 0.694 | 202 (15.23) | 0.452 | 376 (16.18) |
Lesser curve-Greater curve | 85 (5.48) | 0.294 | 85 (6.41) | 0.218 | 126 (5.42) |
Lesser curve-Overlapping/NOS | 247 (15.95) | < 0.001 | 313 (23.60) | 0.007 | 461 (19.83) |
Radiotherapy | < 0.001 | 0.410 | |||
Yes | 304 (19.61) | 415 (31.30) | 697 (29.99) | ||
No | 1246 (80.39) | 911 (68.70) | 1627 (70.01) | ||
Chemotherapy | < 0.001 | 0.015 | |||
Yes | 535 (34.52) | 785 (59.20) | 1279 (55.03) | ||
No | 1015 (65.48) | 541 (40.80) | 1045 (44.97) | ||
Tumor size (cm) | |||||
< 2 | 354 (22.84) | < 0.001 | 212 (15.99) | < 0.001 | 254 (10.93) |
2-5 | 674 (43.48) | 0.008 | 512 (38.61) | 0.004 | 1012 (43.55) |
> 5 | 420 (27.10) | 0.017 | 413 (31.15) | < 0.001 | 867 (37.31) |
NA | 102 (6.58) | < 0.001 | 189 (14.25) | < 0.001 | 191 (8.21) |
Table 3 Analysis of survival and prognosis of patients with early gastric cancer
Variable | OS (EGC = 1305) or (95%CI) | P value | OS (SRC = 313) or (95%CI) | P value |
Age (yr) | < 0.001 | 0.128 | ||
< 40 | 1 (Reference) | 1 (Reference) | ||
40-60 | 1.189 (0.282-5.015) | 0.813 | 1.071 (0.128-8.947) | 0.950 |
60-80 | 2.246 (0.550-9.174) | 0.260 | 2.072 (0.268-16.012) | 0.485 |
> 80 | 5.516 (1.337-22.753) | 0.018 | 4.204 (0.463-38.177) | 0.202 |
Race | < 0.001 | 0.093 | ||
White | 1 (Reference) | 1 (Reference) | ||
Black | 1.459 (1.053-2.022) | 0.023 | 2.052 (0.878-4.793) | 0.097 |
Black-AI | 1.947 (0.476-7.960) | 0.354 | 0.000 | 0.990 |
Black-API | 0.497 (0.358-0.691) | < 0.001 | 0.471 (0.137-1.271) | 0.124 |
Sex | ||||
Male | 1 (Reference) | 1 (Reference) | ||
Female | 0.610 (0.467-0.797) | < 0.001 | 0.791 (0.383-1.632) | 0.526 |
Tumor size (cm) | 0.057 | 0.700 | ||
< 2 | 1 (Reference) | 1 (Reference) | ||
2-5 | 1.317 (0.982-1.764) | 0.066 | 1.579 (0.707-3.525) | 0.265 |
> 5 | 1.859 (1.161-2.978) | 0.010 | 0.000 | 0.974 |
AJCC stage | ||||
I | 1 (Reference) | 1 (Reference) | ||
II | 1.836 (1.100-3.064) | 0.020 | 0.965 (0.231-4.027) | 0.961 |
Depth | ||||
T1a | 1 (Reference) | 1 (Reference) | ||
T1b | 1.280 (0.962-1.703) | 0.090 | 1.786 (0.810-3.938) | 0.151 |
LNM1 | ||||
N0 | 1 (Reference) | 1 (Reference) | ||
N1-3 | 1.271 (0.859-1.880) | 0.230 | 2.134 (0.883-5.154) | 0.151 |
Histology | 0.045 | |||
Differentiated | 1(Reference) | |||
SRC | 0.636 (0.426-0.950) | 0.027 | ||
Undifferentiated | 1.039 (0.780-1.384) | 0.794 | ||
SRC vs non-SRC | 0.626 (0.427-0.919) | 0.017 |
Table 4 Analysis of survival and prognosis of patients with advanced gastric cancer
Variable | OS (AGC = 3895), or (95%CI) | P value | OS (SRC = 1013), or (95%CI) | P value |
Age (yr) | < 0.001 | < 0.001 | ||
< 40 | 1 (Reference) | 1 (Reference) | ||
40-60 | 1.130 (0.882-1.447) | 0.333 | 1.267 (0.898-1.788) | 0.178 |
60-80 | 1.543 (1.212-1.985) | < 0.001 | 1.578 (1.123-2.218) | 0.009 |
> 80 | 2.936 (2.281-3.780) | < 0.001 | 2.290 (1.528-3.431) | < 0.001 |
Race | < 0.001 | < 0.001 | ||
White | 1 (Reference) | 1 (Reference) | ||
Black | 1.096 (0.973-1.234) | 0.133 | 1.326 (1.057-1.663) | 0.015 |
Black-AI | 1.382 (0.949-2.015) | 0.092 | 2.624 (1.423-4.838) | 0.002 |
Black-API | 0.726 (0.651-0.810) | < 0.001 | 0.800 (0.867-1.205) | 0.041 |
Sex | ||||
Male | 1 (Reference) | 1(Reference) | ||
Female | 0.964 (0.883-1.052) | 0.409 | 1.022 (0.867-1.205) | 0.791 |
Tumor size (cm) | < 0.001 | 0.001 | ||
< 2 | 1 (Reference) | 1 (Reference) | ||
2-5 | 1.026 (0.823-1.280) | 0.817 | 1.031 (0.680-1.565) | 0.885 |
> 5 | 1.211 (0.971-1.511) | 0.089 | 1.415 (0.930-2.152) | 0.105 |
AJCC stage | 0.019 | 0.028 | ||
I | 1 (Reference) | 1 (Reference) | ||
II | 1.227 (0.903-1.667) | 0.191 | 1.946 (0.923-4.102) | 0.080 |
III | 1.584 (1.076-2.330) | 0.020 | 3.050 (1.247-7.458) | 0.015 |
T stage | < 0.001 | < 0.001 | ||
T2 | 1 (Reference) | 1 (Reference) | ||
T3 | 1.384 (1.135-1.689) | 0.001 | 1.857 (1.189-2.899) | 0.006 |
T4 | 2.025 (1.633-2.512) | < 0.001 | 2.615 (1.644-4.161) | < 0.001 |
N stage | < 0.001 | 0.086 | ||
N0 | 1 (Reference) | 1 (Reference) | ||
N1 | 1.241 (1.056-1.459) | 0.009 | 1.061 (0.744-1.512) | 0.745 |
N2 | 1.295 (1.050-1.597) | 0.016 | 1.034 (0.665-1.608) | 0.881 |
N3 | 1.904 (1.549-2.341) | < 0.001 | 1.341 (0.882-2.037) | 0.170 |
Histology | 0.002 | |||
Differentiated | 1 (Reference) | |||
SRC | 1.276 (1.117-1.458) | < 0.001 | ||
Undifferentiated | 1.164 (1.037-1.306) | 0.010 | ||
SRC vs non-SRC | 1.139 (1.030-1.258) | 0.011 | ||
Adjuvant therapy | < 0.001 | |||
Radiotherapy | 0.635 (0.367-1.099) | 0.105 | ||
Chemotherapy | 0.481 (0.388-0.595) | < 0.001 | ||
Radiotherapy + Chemotherapy | 0.414 (0.334-0.512) | < 0.001 | ||
None | 1 (Reference) |
Table 5 Scores of risk factors in the survival prognosis model of advanced gastric signet ring cell carcinoma
Variable | Points | Total points | 3/5-yr survival | Total points |
Age (yr) | 0-56 | 0.9-1 | 0-33 | |
< 40 | 0 | 56-111 | 0.8-0.9 | 33-88 |
40-60 | 18 | 111-146 | 0.7-0.8 | 33-123 |
60-80 | 36 | 146-172 | 0.6-0.7 | 123-149 |
> 80 | 60 | 172-195 | 0.5-0.6 | 149-172 |
Race | 195-215 | 0.4-0.5 | 172-192 | |
White | 15 | 215-235 | 0.3-0.4 | 192-212 |
Black | 37 | 235-257 | 0.2-0.3 | 212-234 |
Black-AI | 92 | 257-283 | 0.1-0.2 | 234-260 |
Black-API | 0 | > 283 | < 0.1 | > 260 |
Tumor size (cm) | ||||
< 2 | 0 | |||
2-5 | 5 | |||
> 5 | 31 | |||
NA | 42 | |||
AJCC stage | ||||
I | 0 | |||
II | 54 | |||
III | 100 | |||
T stage | ||||
T2 | 0 | |||
T3 | 41 | |||
T4 | 67 | |||
Adjuvant therapy | ||||
Radiotherapy | 33 | |||
Chemotherapy | 10 | |||
Radiotherapy + Chemotherapy | 0 | |||
None | 67 |
- Citation: Tian HK, Zhang Z, Ning ZK, Liu J, Liu ZT, Huang HY, Zong Z, Li H. Clinicopathological characteristics and prognosis of gastric signet ring cell carcinoma. World J Clin Cases 2022; 10(29): 10451-10466
- URL: https://www.wjgnet.com/2307-8960/full/v10/i29/10451.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v10.i29.10451